University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

Rhea-AI Summary

HeartSciences (Nasdaq: HSCS) announced on February 5, 2026 that the University of the West of England has adopted its MyoVista Insights™ platform and MyoVista® wavECG™ device as exclusive ECG technologies to create an ECG Education and Technology Reference Center.

The center will be used across UWE cardiac and physiological science programs to train NHS-focused cardiac scientists, provide real-world validation in education and research settings, and support future clinical adoption discussions with NHS trusts, strengthening HeartSciences’ UK positioning.

News Market Reaction – HSCS

-3.75% 1.6x vol

1 alert

-3.75% News Effect

+9.5% Peak Tracked

-$363K Valuation Impact

$9M Market Cap

1.6x Rel. Volume

On the day this news was published, HSCS declined 3.75%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.5% during that session. This price movement removed approximately $363K from the company's valuation, bringing the market cap to $9M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.79 Vol: Volume 58,549 is 1.55x th...

high vol

$2.79 Last Close

Volume Volume 58,549 is 1.55x the 20-day average of 37,690, indicating elevated trading activity pre-announcement. high

Technical Shares at $2.93 are trading below the $3.37 200-day MA and 54.71% below the 52-week high of $6.47, while still 45.77% above the 52-week low of $2.01.

Peers on Argus

HSCS was down 7.86% with elevated volume while peers were mixed: BMRA down 4.98%...

1 Down

HSCS was down 7.86% with elevated volume while peers were mixed: BMRA down 4.98%, SSKN down 7.56%, RSLS up 29.8%, DHAI up 400%, and PAVM flat in sector list but down 5.26% in the momentum scan. Moves were not consistently in one direction, pointing to stock-specific factors.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Platform endorsement deal	Positive	+2.1%	Cibolo Rural Health Networks endorsed MyoVista Insights for 123 hospitals.
Dec 15	Earnings and update	Negative	-3.1%	Reported no meaningful revenue and low cash of about $2.0M.
Dec 15	FDA 510(k) submission	Positive	-3.1%	Submitted MyoVista wavECG device for FDA 510(k) premarket clearance.
Dec 11	Platform upgrade launch	Positive	+0.0%	Launched MyoVista Insights version 1.1 with expanded usability and tools.
Sep 11	Earnings and business update	Negative	-10.0%	Highlighted no meaningful revenue and going-concern risks alongside tech progress.

Pattern Detected

News and partnership wins often see modest or negative next-day moves, while fundamentally negative earnings updates have coincided with sharper declines.

Recent Company History

Over the last six months, HSCS has focused on commercializing its AI‑ECG ecosystem. Key steps included the Dec 11, 2025 commercial launch of MyoVista Insights version 1.1 and the Dec 15, 2025 FDA 510(k) submission for the MyoVista wavECG device. Earnings updates on Sep 11, 2025 and Dec 15, 2025 highlighted minimal revenue and funding needs, with negative price reactions. The Jan 29, 2026 Cibolo partnership showed a small positive move. Today’s UWE adoption extends this commercialization and reference-site strategy.

Market Pulse Summary

This announcement highlights expansion of HeartSciences’ ECG ecosystem into UK academic and training...

Analysis

This announcement highlights expansion of HeartSciences’ ECG ecosystem into UK academic and training settings. UWE’s exclusive use of MyoVista Insights and MyoVista wavECG across cardiac science programs creates a reference center that may support future NHS discussions and real‑world validation. In context of earlier milestones—such as the Dec 11, 2025 MyoVista Insights 1.1 launch and Dec 15, 2025 FDA 510(k) submission—investors may watch for concrete revenue traction, additional institutional adoptions, and updates on regulatory progress.

Key Terms

electrocardiography, ecg, ekg, artificial intelligence, +1 more

5 terms

electrocardiography medical

"a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”)"

Electrocardiography is a medical test that records the heart’s electrical signals using sensors on the skin, producing a tracing that shows heart rhythm and timing. Investors should care because these readings are routinely used to assess the safety and effectiveness of drugs, medical devices, and treatments—like checking a building’s wiring for faults—so abnormal results can affect clinical trial outcomes, regulatory approval, and product marketability.

ecg medical

"advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence"

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

ekg medical

"advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence"

An EKG is a short test that records the heart’s electrical activity using sensors on the skin, producing a simple tracing like a road map of each heartbeat. Investors care because EKG results are used to spot heart-related side effects or safety signals in drug trials and medical devices, and clear or abnormal EKG findings can affect regulatory approval, trial continuation, product liability, and market value.

artificial intelligence technical

"through the integration of artificial intelligence (“AI”), today announced that the University"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

cardiac electrophysiology medical

"engage in detailed, quantitative ECG analysis, supporting a deeper understanding of cardiac electrophysiology and pathology."

The medical specialty that studies and treats the heart’s electrical system — how electrical signals start and travel to make the heart beat and what causes irregular heart rhythms. It matters to investors because tests, procedures and devices from this field (like diagnostic tools, catheters, implants and drugs) drive clinical demand, regulatory reviews and company revenue; think of it as the “wiring and circuit-breakers” sector for the heart that determines market opportunity for related technologies.

AI-generated analysis. Not financial advice.

Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company’s MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology.

Under the agreement, MyoVista Insights and the MyoVista wavECG device will be used exclusively across UWE’s cardiac and physiological science teaching programs to train the next generation of cardiac scientists. UWE is one of the UK’s largest providers of Cardiac Healthcare Science and Physiological Science education, delivering a nationally aligned portfolio of programs that directly support NHS England workforce priorities and contribute meaningfully to the UK’s cardiac diagnostic capacity.

The establishment of the UWE ECG Education and Technology Reference Center creates a nationally aligned academic reference site that supports future clinical adoption discussions with NHS trusts, provides real-world validation of MyoVista Insights™ in education and research settings, and strengthens HeartSciences’ long-term commercial positioning within the UK healthcare ecosystem.

Duncan Sleeman, Senior Lecturer in Cardiac Physiology and Programme Lead (PGCert Echocardiography) at UWE, and Senior Practice Educator for Healthcare Sciences at NHS England Southwest, commented, “HeartSciences’ MyoVista Insights platform represents a significant advance over traditional ECG systems. It enables students to move beyond paper-based pattern recognition and engage in detailed, quantitative ECG analysis, supporting a deeper understanding of cardiac electrophysiology and pathology. Even at this early stage of adoption, we are seeing clear benefits in student engagement, confidence, and diagnostic insight, alongside valuable opportunities for undergraduate and postgraduate research. This directly supports the development of a digitally literate, analytically skilled, and future-ready NHS cardiac diagnostic workforce.”

Andrew Simpson, Chief Executive Officer of HeartSciences, added, “We are delighted that UWE has selected HeartSciences to establish an ECG Education and Technology Reference Center. Training the next generation of NHS cardiac scientists on MyoVista Insights not only reinforces the clinical and educational value of our platform but also creates a strategically important reference site that supports our broader commercial engagement with the NHS in the UK.”

About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions

For more information, please visit: www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025  and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us

Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com

FAQ

What did HeartSciences (HSCS) announce with the University of the West of England on February 5, 2026?

They announced UWE will adopt MyoVista Insights and the MyoVista wavECG as exclusive ECG technologies to create an ECG Education and Technology Reference Center. According to the company, the center supports training, research, and NHS clinical adoption discussions in the UK.

How will the UWE reference center affect HeartSciences' commercial position in the UK (HSCS)?

The agreement is intended to strengthen HeartSciences’ long-term commercial positioning within the UK healthcare ecosystem. According to the company, the reference site supports real-world validation and future engagement with NHS trusts and stakeholders.

What role will MyoVista Insights and wavECG play in UWE’s cardiac education programs?

They will be used exclusively across UWE’s cardiac and physiological science teaching programs to train students on quantitative ECG analysis. According to UWE comments, the tools improve student engagement, confidence, and research opportunities in cardiac diagnostics.

Does the UWE adoption suggest clinical validation or only educational use for HSCS technology?

The announcement indicates both educational deployment and real-world validation in education and research settings. According to the company, the reference center will support future clinical adoption discussions with NHS trusts, linking education and clinical outreach.

What immediate benefits did UWE report from using MyoVista for students and research?

UWE reported improved student engagement, confidence, and diagnostic insight when using MyoVista for quantitative ECG analysis. According to UWE faculty quoted, this also creates valuable undergraduate and postgraduate research opportunities aligned with NHS workforce priorities.